Arcellx (NASDAQ:ACLX) Sets New 1-Year High - Should You Buy?

2026-04-03 08:38:43 ET

Arcellx, Inc. ( NASDAQ:ACLX – Get Free Report )’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $114.94 and last traded at $114.8950, with a volume of 455581 shares traded. The stock had previously closed at $114.82.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Needham & Company LLC cut shares of Arcellx from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. William Blair lowered shares of Arcellx from a “strong-buy” rating to a “hold” rating in a report on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcellx in a research note on Wednesday, January 21st. HC Wainwright cut shares of Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 price target on the stock. in a research report on Monday, February 23rd. Finally, Canaccord Genuity Group set a $115.00 price target on shares of Arcellx in a research note on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Arcellx has a consensus rating of “Hold” and an average target price of $111.87.

Read Our Latest Research Report on ACLX

Arcellx Stock Performance

The stock has a market capitalization of $6.71 billion, a PE ratio of -28.20 and a beta of 0.25. The stock’s 50-day moving average price is $95.02 and its two-hundred day moving average price is $83.36.

Arcellx ( NASDAQ:ACLX – Get Free Report ) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.01). Arcellx had a negative net margin of 1,027.26% and a negative return on equity of 55.42%. The business had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $13.40 million. On average, analysts predict that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Rami Elghandour sold 89,916 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the completion of the transaction, the insider owned 276,051 shares of the company’s stock, valued at $31,447,729.92. This trade represents a 24.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink . Also, insider Christopher Heery sold 7,437 shares of Arcellx stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total value of $487,197.87. Following the transaction, the insider owned 29,631 shares of the company’s stock, valued at $1,941,126.81. The trade was a 20.06% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 109,366 shares of company stock valued at $11,526,708. 8.35% of the stock is owned by corporate insiders.

Institutional Trading of Arcellx

Institutional investors and hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. raised its holdings in Arcellx by 66.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,560,425 shares of the company’s stock worth $688,540,000 after buying an additional 4,208,069 shares during the last quarter. Vestal Point Capital LP increased its position in shares of Arcellx by 134.0% during the fourth quarter. Vestal Point Capital LP now owns 2,925,000 shares of the company’s stock valued at $190,710,000 after acquiring an additional 1,675,000 shares in the last quarter. Paradigm Biocapital Advisors LP increased its holdings in shares of Arcellx by 23.1% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 5,724,016 shares of the company’s stock worth $373,206,000 after purchasing an additional 1,075,000 shares in the last quarter. Decheng Capital LLC increased its holdings in shares of Arcellx by 995.2% in the 2nd quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock worth $36,060,000 after purchasing an additional 497,609 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Arcellx by 31.0% in the fourth quarter. State Street Corp now owns 1,998,503 shares of the company’s stock worth $130,302,000 after purchasing an additional 472,476 shares during the last quarter. 96.03% of the stock is currently owned by institutional investors.

About Arcellx

( Get Free Report )

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.

See Also

• Five stocks we like better than Arcellx